PN-943
Investigational — oral IBD peptide (PN-943) — not approved.
What it's for
PN-943 is an still being studied oral peptide designed to block α4β7 integrin interactions with limited systemic exposure.
What it does for the body
Studied for ulcerative colitis by reducing lymphocyte trafficking to gut mucosa. Not approved. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
α4β7 blockade impairs homing of inflammatory lymphocytes to intestinal tissue (same pathway class as vedolizumab, but oral peptide approach). Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.
Research context
Bottom line for readers: PN-943 is still being studied in people. Watch for peer-reviewed trial readouts and regulator decisions — not just social-media summaries.
Studied for (literature interest)
- Digestive research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: PN-943 — FDA.gov search
- ClinicalTrials.gov search: PN-943 — U.S. clinical trials registry
- Drugs@FDA search: PN-943 — FDA drug database (if approved)
- PubMed search: PN-943 — NCBI PubMed
- PubMed Central search: PN-943 — NCBI PMC
Reference
No ref on file.